Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novartis AG (NYSE:NVS)

83.80
Delayed Data
As of Dec 11
 -0.16 / -0.19%
Today’s Change
69.01
Today|||52-Week Range
86.90
+15.05%
Year-to-Date
Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta
Dec 11 / Zacks.com - Paid Partner Content
Mylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest
Dec 04 / Zacks.com - Paid Partner Content
Novartis Reports Updated Results from Kymriah's JULIET Study
Dec 11 / Zacks.com - Paid Partner Content
Lilly's (LLY) Taltz Gets Approval for Label Expansion in US
Dec 04 / Zacks.com - Paid Partner Content
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
Dec 11 / Zacks.com - Paid Partner Content
5 Biotech and Pharma Stocks with FDA Catalysts this December
Nov 30 / Zacks.com - Paid Partner Content
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi
Dec 11 / Zacks.com - Paid Partner Content
How Will U.S. Tax Reform Impact Pharma/Biotech Industry?
Nov 29 / Zacks.com - Paid Partner Content
Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend
Dec 08 / TheStreet.com - Paid Partner Content
Regeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail
Nov 28 / Zacks.com - Paid Partner Content
Puma (PBYI) Stock Up More than 200% This Year: Here's Why
Dec 08 / Zacks.com - Paid Partner Content
2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17
Nov 28 / Zacks.com - Paid Partner Content
Gilead Sciences to Acquire Cell Design Labs for $567 Million
Dec 08 / Zacks.com - Paid Partner Content
Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%
Nov 28 / Zacks.com - Paid Partner Content
Pfizer Reports Updated Data from Phase III Study on Ibrance
Dec 07 / Zacks.com - Paid Partner Content